Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China
· Delayed Price · Currency is CNY 7.12
+0.45 (6.75%)
Apr 30, 2026, 11:04 AM CST
SHA:603567 Revenue
Heilongjiang ZBD Pharmaceutical had revenue of 204.78M CNY in the quarter ending September 30, 2025, a decrease of -44.14%. This brings the company's revenue in the last twelve months to 1.59B, down -48.84% year-over-year. In the year 2024, Heilongjiang ZBD Pharmaceutical had annual revenue of 2.70B, down -13.84%.
Revenue (ttm)
1.59B
Revenue Growth
-48.84%
P/S Ratio
3.93
Revenue / Employee
678.98K
Employees
2,349
Market Cap
6.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.70B | -434.25M | -13.84% |
| Dec 31, 2023 | 3.14B | -1.08B | -25.53% |
| Dec 31, 2022 | 4.21B | 87.33M | 2.12% |
| Dec 31, 2021 | 4.13B | 723.07M | 21.24% |
| Dec 31, 2020 | 3.40B | 111.89M | 3.40% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Jan 1, 2019 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tianjin Tianyao Pharmaceuticals | 2.73B |
| Beijing Sun-Novo Pharmaceutical Research | 1.19B |
| Hunan Jiudian Pharmaceutical | 3.01B |
| ChengDa Pharmaceuticals | 406.37M |
| Tibet Duo Rui Pharmaceutical | 177.11M |
| Jinghua Pharmaceutical Group | 1.46B |
| Guizhou Xinbang Pharmaceutical | 5.62B |
| Shanghai Kaibao Pharmaceutical CO.,Ltd | 1.17B |